Gold Entertainment Group Inc (GEGP)

[JellyDonut]

Kathrin Kortschak
Partner at Hestia Investments
Director, Sutura Therapeutics

http://www.suturatherapeutics.com/

Keith Foster
Chief Scientific Officer at Sutura Therapeutics.
Sutura Therapeutics own the intellectual property of a technologies to enhance the delivery of antisense oligonucleotides. Sutura Therapeutics' pipeline includes a DMD product using this technology.
E-mail [e-mail]

I am a translational biologist with 21 years’ experience in developing gene, cell and pharmaceutical medicines for Duchenne muscular dystrophy (DMD) and metabolic diseases. I currently run a state of the art research lab at the University of Reading that is able to facilitate medicine development and subsequent analyses in pre-clinical disease models.

Current programs included:
1. Optimising delivery of antisense oligonucleotides.
2. Viral and pharmaceutical mediated approaches to counter oxidative stress.
3. Novel approaches to induce immune tolerance to neo-antigens.
4. Antisense oligonucleotide mediated approaches to muscle augmentation for muscular dystrophy and metabolic diseases.